Please login to the form below

Not currently logged in
Email:
Password:

EMA’s Stella Blackburn appointed president of International Society for Pharmacoepidemiology

Will continue as Agency’s risk management development and scientific lead

EMA Stella BlackburnThe European Medicines Agency's (EMA) Stella Blackburn (pictured) has been appointed president of the International Society for Pharmacoepidemiology, a non-profit organisation that aims to advance public health by taking an epidemiologic approache to the study of pharmaceutical products.

Dr Blackburn will carry out her new role on a voluntary basis for one year in addition to her work at the Agency, where she is risk management development and scientific lead.

"I feel very honoured to have been asked to take on this role," she said. "During my presidency, I will continue to promote the European Union viewpoint and the key role of the Agency in protecting the health of Europeans.”

“I also want to continue to support its global expansion, providing training for the next generation of pharmacoepidemiologists and developing pharmacoepidemiology expertise around the world."

Dr Blackburn has been with the EMA since 1997 serving in several roles, including as specialised group leader for the cardiovascular, oncology, haematology and diagnostics group in the pharmacovigilance, post-authorisation safety and efficacy sector.

She was also risk management co-ordinator from 2004 to 2009, during which time she was lead author of the EU risk management guideline.

In her current EMA role, she is involved in developing the Agency's policy and procedures for risk management, and she is on the steering group for the European Network of Centres of Pharmacoepidemiology and Pharmacovigilance.

13th September 2012

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics